Top Tweets for #inavolisib
Check our recent consensus-based treatment guideline on the use of #Inavolisib, #Palbociclib, and #Fulvestrant for ER+/HER2- #MBC. Huge thanks to Guilherme Nader-Marta, MD, (@GuiNaderMarta) for his leadership in the consensus discussions and in writing of the recommendation statements. #MetastaticBreastCancer #BreastCancer #CDK46
We have seen a few updates on PI3K I at #SABCS25! Here is the table we’ve used (common AEs, HbA1C inclusion, & dose⬇️) during our discussion on #Inavolisib, #Capivasertib, and #Alpelisib in HR+ mBC w/ @Neil_Iyengar & #DrGallagher
#OncTwitter #MedTwitter @OncoAlert @OncUpdates
ToxCheck: AEs for PI3K inhibitors & how to manage them when treating HR+ breast cancer w/ @Neil_Iyengar & #DrGallagher
✅ Inavolisib
✅ Capivasertib
✅ Alpelisib
Full 🗣️:
⭐️ https://t.co/Gax1SY7fRA
⭐️ Also on “Oncology Brothers” podcast
#OncTwitter @OncUpdates @OncoAlert
In endocrine-resistant HR+ #BreastCancer 🎀 with #PIK3CA mutation, #Inavolisib+ Palbociclib + Fulvestrant showed mPFS 17 mo and mOS 34 mo
How to overcome endocrine resistance in PIK3CA-negative patients? 🤔
#62OncologyCongress 🇷🇸
@OncoAlert
🎥 #ASCO2025 In-Depth! @FrancoisDuhoux & @ElisaAgostinett on DESTINY-Breast09:
✔️ +13 mo PFS (T-DXd + p) > THP
✔️ 21% d/c due to AEs
✔️ ILD risk noted
✔️ Target: aggressive HER2+ MBC
👀 Watch now https://t.co/v4Gf0RbGFN #MediMix #BreastCancer #MBC #Inavolisib #PI3Kinhibitor
Presented at #ASCO25, #Inavolisib combo reduces death risk by 30% in #PIK3CA+ HR+/HER2- advanced #breastcancer. Median OS: 34 vs 27 months. PFS nearly doubles.
https://t.co/hfut4eoBRj
#Cancer #Oncology #CancerResearch
Data from Ph I/Ib trials - #Inavolisib in PIK3CA-mut HR+/HER2– mBC
- 58% of pts prediabetic/obese
⚠️ 81% developed hyperglycemia (HG); 35% grade 3–4
- 86% resolved; 42% had dose interruptions
Most common anti-HG meds: metformin (53%), SGLT2-i (26%), DPP4-i (23%)
@OncoAlert
OS data from INAVO120 trial out in @NEJM
Inavolisib + palbo+fulv vs placebo combo in PIK3CA-mut HR+ MBC
‼️OS 34 vs 27 mo (HR 0.67, 0.5–0.9, P=0.02)
PFS 17 vs 7 mo (HR 0.42)
ORR 63 vs 28% (P<0.01)
⚠️ Discont due to AE 6.8% vs 0.6%
⬆️ hyperglycemia & mucositis
@OncoAlert
Second @NEJM from the oral advanced #BreastCancer session at #ASCO25: improved overall survival with the triplet (combination of #inavolisib + #palbociclib + #fulvestrant) in endocrine resistant #PIK3CAm disease
@OncoAlert @ASCO
Final OS data @ASCO for #Inavolisib
🔥INAVO120: 1L HR+, HER2- mBC, PIK3CAm
Inavolisib + palbo + fulv vs placebo combo:
mOS: 34 vs 27 mo (HR 0.67, 95% CI 0.50–0.91)
mPFS: 17.2 vs 7.3 mo
ORR: 62.7% vs 28%
Discover more: https://t.co/BuZo38ICxP @larvol
#LARVOL
Oncologist buzz on X (formerly Twitter) with Roche's release for INAVO120 trial - Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced #breastcancer.
#LARVOL #CancerResearch #Oncology #OncologyInsights #INAVO120
Itovebi, FDA approved for treating HR+/HER2- metastatic breast cancer with an abnormal PIK3CA gene.
Visit 🔗 https://t.co/1OX4aQ5mOZ
#WingsMed #pharmacy #Speciality #Medicines #OnlinePharmacy #Inavolisib #Cancer #Tablets
ホルモン受容体陽性HER2陰性 #PIK3CA変異 陽性内分泌療法抵抗性の進行乳がんに対する1次治療として、パルボシクリブとフルベストラントの併用療法に経口PI3Kα阻害薬 #inavolisib を加えて投与することはプラセボ追加と比べて有意に全生存期間を延長できることが分かりました
https://t.co/Rhf2PuQ0DE
2024 approvals: Summary of 8 new drugs/indications in #BreastCancer & #GynOnc by @US_FDA
1. #Ribociclib
2. #Inavolisib
3. #Pembrolizumab x2
4. #Mirvetuximab
5. #Tisotumab
6. #Dostarlimab
7. #Durvalumab
#bcsm #gyncsm #OncTwitter #MedTwitter #HappyHolidays
In 2023, 3 more drugs/indications were approved for #BreastCancer by @FDAOncology @US_FDA:
- #Elacestrant in ESR1 HR+
- #Sacituzumab in endocrine resistant HR+
- #Capivasertib in AKT1/PIK3CA/PTEN mutation HR+
#bcsm #OncTwitter #MedTwitter #oncology @ThanksCancer
#SABCS24 Day 1 Highlights #CommunityOnc:
1. @FDAOncology Reviews recent approvals: #Ribociclib & #Inavolisib
2. #PADMA: HR+ ET + CDK4/6i vs Chemo 1L
3. #DB06: HR+ TDXd
4. #KN522: biomarker analysis
@SABCSSanAntonio @AACR #bcsm #OncTwitter
1/5
#PIK3CA変異陽性 #ホルモン受容体陽性 #HER2陰性 の局所進行性または転移性 #乳がん に対する #Inavolisib＋#イブランス＋#フェソロデックス 併用療法の有効性、安全性を比較検証した試験の結果が医学誌『The New England Journal of Medicine』にて公表されました。
https://t.co/WRaBi9LM0s
The INAVO120 trial, funded by @Roche looked at whether a new drug called #Inavolisib, plus #Palbociclib and a hormone therapy drug could delay the progression of advanced breast cancer.
Check out Dr. Komal Jhaveri @jhaveri_komal @MSKCancerCenter discussing the recent #Inavolisib FDA approval @FDAOncology focusing on clinical implications & best practices
Full📽️on #VuMedi
👇
https://t.co/r3yzF7we2z
#bcsm #breastcancer @US_FDA #OncTwitter
ホルモン療法抵抗性HER2陰性PIK3CA変異陽性の進行 #乳がん を対象に、経口 #PI3Kα阻害薬 #inavolisib がパルボシクリブとフルベストランとの併用で米国で承認されました。日本でも早く使えるようになってほしいです。
https://t.co/RSrRCjF4kV
#Inavolisib now @US_FDA approved based off #INAVO120: Ph III, Inavolisib (iPI3Ka) + Fulv + Palbo vs Palbo/Fulvestrant HR+ metastatic breast cancer:
- OS immature (favoring Inavo HR 0.64)
- PFS 15.0 vs 7.3mos (HR 0.43)
- AEs: >50% hyperglycemia & stomatitis
#bcsm #OncTwitter
#中外製薬株式会社 は、PIK3CA遺伝子変異を有する #ホルモン受容体陽性 #HER2陰性 の進行性 #乳がん に対して開発中のPI3Kα阻害剤 #inavolisib について、エフ・ホフマン・ラ・ロシュ社と導入契約を締結したことを発表しました。
https://t.co/RN1mRvSbVo
術後内分泌療法抵抗性のPIK3CA変異陽性ホルモン受容体陽性HER2陰性局所進行転移 #乳がん に対するPI3Kα阻害薬である #Inavolisib＋#イブランス+#フェソロデックス 併用療法の有効性、安全性を比較検証した第3相のINAVO120試験の結果が #米国臨床腫瘍学会 にて公表されました。
https://t.co/cwlQT082gs
On the way to #AACR24! Ready to discuss our work on resistance to PIK3CA inhibitors in breast cancer and beyond! @AACR @MGHCancerCenter @harvardmed #SanDiego #PIK3CA #alpelisib #inavolisib #bcsm #CorcoranLab
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.3M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.3M followers
Bill Gates
@billgates
65.1M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers